Dermata Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
DRMA$0.76+0.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| For the three months ended June 30, | For the six months ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses: | ||||
| Research and development | $212,563 | $617,835 | $596,287 | $1,898,976 |
| Selling, general and administrative (including related party amounts of $428,966 and $619,549 for the three and six months ended June 30, 2026, respectively, and $0 for the three and six months ended June 30, 2025) | 2,801,004 | 1,154,896 | 4,343,662 | 2,213,559 |
| Total operating expenses | 3,013,567 | 1,772,731 | 4,939,949 | 4,112,535 |
| Loss from operations | (3,013,567) | (1,772,731) | (4,939,949) | (4,112,535) |
| Other income and expenses: | ||||
| Interest income | 46,504 | 71,638 | 125,180 | 107,855 |
| Net loss | $(2,967,063) | $(1,701,093) | $(4,814,769) | $(4,004,680) |
| Net loss per share of Common Stock, basic and diluted | $(0.74) | $(1.66) | $(1.22) | $(5.18) |
| Weighted-average basic and diluted Common Stock | 4,022,143 | 1,026,506 | 3,940,983 | 772,397 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.